Restless Leg Syndrome Global Market Report 2025

The restless leg syndrome market size has grown rapidly in recent years. It will grow from $1.91 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth during the historic period can be attributed to factors such as rising alcohol consumption, expanded health insurance coverage, greater availability of over-the-counter medications, increased public health initiatives, and a rise in mental health concerns.

The restless leg syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.59 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth during the forecast period can be attributed to factors such as increased healthcare investment, awareness and education campaigns, a rise in early diagnoses, higher government funding, and greater participation in clinical trials. Key trends in the forecast period include AI-powered personalized treatment plans, next-generation neurostimulation devices, deep learning algorithms for diagnosis, brainwave modulation technology, and wearable exoskeletons designed to assist with leg movements.

The growing prevalence of iron deficiency is expected to drive the expansion of the restless leg syndrome (RLS) market. Iron deficiency is a condition in which the body lacks sufficient iron to produce enough healthy red blood cells, leading to symptoms such as fatigue, weakness, and pale skin. The rise in iron deficiency cases is attributed to factors such as poor dietary intake, blood loss, malabsorption disorders, and increased iron demands during pregnancy or growth. Treatment for restless leg syndrome often includes iron supplementation or dietary adjustments, which not only help alleviate the discomforting urges and sensations but also address the underlying iron deficiency by replenishing iron stores, improving red blood cell production, and restoring proper neurological function. For example, in January 2025, NHS England reported that in the 2023-24 period, there were 191,927 admissions due to iron deficiency, reflecting an 11% increase from the previous year. As a result, the rising prevalence of iron deficiency is fueling the growth of the RLS market.

Leading companies in the RLS market are focusing on developing innovative, non-invasive therapies to improve symptom management and patient outcomes. Non-invasive therapies are medical treatments that do not require surgery or skin penetration, offering relief through advanced techniques such as electrical stimulation, light therapy, or external devices. For example, in April 2023, Varco Leg Care, an India-based consumer health-technology company, received FDA De Novo approval for its NTX100 Tonic Motor Activation (TOMAC) System. This system is designed to treat moderate to severe RLS symptoms and improve sleep quality in patients who do not respond to medications. The device works by electrically activating the peroneal nerves on both sides of the body to produce tonic, sustained muscle activation, which aids in suppressing RLS symptoms while being compatible with sleep.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for an undisclosed amount. This acquisition aims to strengthen Amgen’s portfolio in rare and inflammatory diseases, drive revenue growth, and develop innovative treatments while improving patient access to medications. Horizon Therapeutics plc, an Ireland-based biotechnology company, is involved in the treatment of restless leg syndrome.

Major players in the restless leg syndrome market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Novartis International AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter International Inc., Astellas Pharma Inc., UCB S.A., Kyowa Kirin Co Ltd., Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Mundipharma International Limited, Azurity Pharmaceuticals LLC, Otsuka Pharmaceutical Co Ltd., Horizon Therapeutics plc, Mylan N.V., Apollo Pharmacy Limited.

Europe was the largest region in the restless leg syndrome market in 2024. North-America is expected to be the fastest-growing region in the forecast period. The regions covered in restless leg syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the restless leg syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Restless Leg Syndrome (RLS) is a neurological disorder defined by an overwhelming urge to move the legs, often caused by uncomfortable sensations. Treatment options include lifestyle modifications, iron supplements, medications that influence dopamine levels, and methods to enhance sleep hygiene.

The primary types of restless leg syndrome are primary restless leg syndrome and secondary restless leg syndrome. Primary restless leg syndrome occurs when the symptoms of restless legs appear without any underlying medical condition. Treatments for these conditions include medicines, devices, and, in some cases, surgery. These treatments are available through different routes of administration, such as oral and injectable forms. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are used in a range of applications such as neurological care, sleep disorder management, movement disorders, and symptom control.

The restless leg syndrome market research report is one of a series of new reports that provide restless leg syndrome market statistics, including restless leg syndrome industry global market size, regional shares, competitors with a restless leg syndrome market share, detailed restless leg syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the restless leg syndrome industry. This restless leg syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The restless leg syndrome market consists of sales of benzodiazepines, sleep aids, transdermal patches, non-pharmacological therapies, and lifestyle management tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.